WashU Researchers Plan Major Trial Of Noninvasive Radiation Ablation For Ventricular Tachycardia
Executive SummaryPhysicians developing a promising technique for noninvasive cardiac radioablation for ventricular tachycardia are working with US FDA to develop a large multicenter trial of their technique following the success of a five-patient case-series and an 18-patient prospective study.
You may also be interested in...
A five-patient trial shows that cardiac ablation with noninvasive stereotactic cardiac radiotherapy can reduce the burden of ventricular tachycardia. The technique could be a major improvement over catheter ablation, because its non-invasive and would allow for access to areas of the ventricular tachycardia that are inaccessible to catheter ablation. But more trials are needed to refine the technique and improve safety.
CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. Current clinical trials are examining the use of CyberHeart not only for atrial fibrillation (AF) treatment, but also for ventricular tachycardia, for which a US pivotal trial is scheduled for early 2017.
Although immunotherapy and other cutting-edge technologies have dominated the spotlight in cancer treatment over the last several years, the use of radiation therapy is rapidly increasing as physicians look to this non-invasive, cost-effective treatment to address a broad and growing number of cancers. Valued at nearly $4.3 billion in 2015, the global radiation therapy market is growing at a CAGR of 5.5%, and is projected to reach $5.6 billion by 2020, according to a recent report from Medtech Insight.